actavis inc (ACT:New York Consolidated)
Executive Profile*
Catherine M. KlemaIndependent Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee, Actavis, Inc. |
| Age | Total Calculated Compensation | This person is connected to 9 board members in 1 different organizations across 3 different industries. See Board Relationships |
| 53 | $307,472 |
Background*
Ms. Catherine M. Klema serves as the President of Nettleton Advisors LLC. Ms. Klema is responsible for assisting healthcare clients in developing acquisition strategies, analyzing business prospects and executing transactions at Nettleton Advisors, a consulting firm established by her in 2001. She served as Managing Director of Healthcare Investment Banking at SG Cowen Securities from 1997 to 2001. She served as the Senior Vice President for Lehman Brothers. While at ...
Corporate Headquarters*Morris Corporate Center IIIParsippany, New Jersey 07054 United States Phone: 862-261-7000 Fax: -- Board Members Memberships*2000-2011 Former Director, Member of Nominating & Governance Committee and Member of Compensation Committee 2004-Present Independent Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
Education*There is no Education data available.Other Affiliations* |
Annual Compensation*There is no Annual Compensation data available.Stock Options*There is no Stock Options data available.Total Compensation*
|
| Recently Viewed | |||
| ACT:US | $128.55 USD | -1.49 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| Dilip Shantilal Shanghvi | Managing Director, Promoter executive Director and Member of Shareholders/Investors Grievance Committee Sun Pharmaceutical Industries Limited | -- |
| Heather Bresch | Chief Executive Officer, Director and Member of Science & Technology Committee Mylan, Inc. | $998.1K |
| J. Michael Pearson | Chairman and Chief Executive Officer Valeant Pharmaceuticals International, Inc. | $1.7M |
| Flemming Ornskov M.D., MBA, MPH | Chief Executive Officer, Head of Human Genetic Therapies and Director Shire plc | -- |
| Frederic Roch Doliveux DVM | Chief Executive Officer and Executive Director UCB SA | €1.8M | Compensation as of Fiscal Year --. |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ACTAVIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
